30,464 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCRFree Report) in the third quarter, HoldingsChannel.com reports. The firm acquired 30,464 shares of the company’s stock, valued at approximately $1,337,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Assetmark Inc. grew its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Janney Capital Management LLC bought a new position in Structure Therapeutics in the 3rd quarter worth about $290,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Structure Therapeutics by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,460 shares of the company’s stock valued at $503,000 after purchasing an additional 5,707 shares during the period. abrdn plc raised its holdings in shares of Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $36.37 on Thursday. The business has a fifty day simple moving average of $39.48 and a 200-day simple moving average of $39.87. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $66.38.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of analyst reports. Morgan Stanley assumed coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, JMP Securities dropped their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics currently has an average rating of “Buy” and a consensus target price of $86.80.

Read Our Latest Stock Report on GPCR

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Recommended Stories

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. (NASDAQ:GPCRFree Report).

Institutional Ownership by Quarter for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.